Diagnosis and management of polymyalgia rheumatica/giant cell arteritis

BioDrugs

Volumn 9, Issue 1, 1998, Pages 25-32

  Salvarani, Carlo ^a,d   Macchioni, Luigi ^a   Olivieri, Ignazio ^b   Cantini, Fabrizio ^c   Boiardi, Luigi ^a  

^a Azienda Ospedaliera Arcisp S M   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MISERICORDIA E DOLCE HOSPITAL   (Italy)

^d Unita Reumatologica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ARTICLE; CLINICAL EXAMINATION; CORTICOSTEROID THERAPY; ERYTHROCYTE SEDIMENTATION RATE; FROZEN SHOULDER; GIANT CELL ARTERITIS; HUMAN; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE STIFFNESS; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; VERTEBRA FRACTURE;

EID: 0031983321     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809010-00003     Document Type: Article

References (51)

1. Barber HS. Myalgic syndrome with constitutional effects: polymyalgia rheumatica. Ann Rheum Dis 1957; 16: 230-7
2. Chung T-Y, Hunder GG, Hstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 672-80
3. Salvarani C, Macchioni PL, Tartoni PL, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987; 5: 205-15
4. O'Duffy JD, Hunder GG, Wahner HW. A follow-up study of polymyalgia rheumatica: evidence of chronic axial synovitis. J Rheumatol 1980; 7: 685-93
5. Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984; 13: 322-8
6. Ahmed T, Braun AI. Carpal tunnel syndrome with polymyalgia rheumatica. Arthritis Rheum 1978; 21: 221-3
7. Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica: report of nineteen cases. Arthritis Rheum 1996; 39: 73-80
8. McCarty DJ, O'Duffy JD, Pearson L, et al. Remitting seronegative symmetrical synovitis with pitting edema: RS3PE syndrome. JAMA 1985; 254: 2763-7
9. Olivieri I, Salvarani C, Cantini F. Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases? J Rheumatol 1997; 24: 249-52
10. Olivieri I, Salvarani C, Cantini F, et al. Distal extremity swelling with pitting edema in polymyalgia rheumatica: a case studied with magnetic resonance imaging. Clin Exp Rheumatol. In press
11. Bird HA, Esselinckx W, Dixon ASJ, et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979; 38: 434-9
12. Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum 1996; 39: 304-7
13. Ellis ME, Ralston S. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. Ann Rheum Dis 1983; 42: 168-70
14. Salvarani C, Boiardi L, Macchioni L, et al. Polymyalgia rheumatica [letter]. Lancet 1996; 348: 550-1
15. Arnold MH, Corrigall VM, Pitzalis C, et al. The sensitivity and specificity of reduced CD8 lymphocyte levels in the diagnosis of polymyalgia rheumatica/giant cell arteritis. Clin Exp Rheumatol 1993; 11: 629-34
16. Salvarani C, Boiardi L, Macchioni PL, et al. On the utility of CD8 level assessment in the diagnosis of polymyalgia rheumatica/giant cell arteritis [letter]. Clin Exp Rheumatol 1995; 13: 129-30
17. Salvarani C, Macchioni PL, Boiardi L, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in Northern Italy. Arthritis Rheum 1991; 34: 351-6
18. Noltorp S, Svensson B. High incidence of polymyalgia rheumatica and giant cell arteritis in a Swedish community. Clin Exp Rheumatol 1991; 9: 351-5
19. Salvarani C, Gabriel S, O'Fallon M, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123: 192-4
20. Hall S, Lie JY, Kurland LT, et al. The therapeutic impact of temporal artery biopsy. Lancet 1983; II: 1217-22
21. Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis. Ann Intern Med 1994; 120: 987-92
22. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8
23. Fernandez-Sueiro L, Gonzalez-Gay M, Armona J, et al. Validation of the 1990 American College of Rheumatology criteria for the classification of giant cell arteritis (GCA) [abstract]. Arthritis Rheum 1993; 36: S138
24. Kyle V, Cawston TE, Hazleman BL. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis. Ann Rheum Dis 1989; 48: 667-71
25. Gudmundsson M, Nordborg E, Bengtsson BA, et al. Plasma viscosity in giant cell arteritis as a predictor of disease activity. Ann Rheum Dis 1993; 52: 104-9
26. Pountain GD, Calvin J, Hazleman BL. Alfa-1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1994; 33: 550-4
27. Kyle V, Hazleman BL. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. BMJ 1990; 300: 344-5
28. Andersson R, Malmvall B-E, Bengtsson B-A. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986; 220: 465-9
29. Ayoub WT, Franklin CM, Torretti D. Polymyalgia rheumatica: duration of therapy and long-term outcome. Am J Med 1985; 79: 309-15
30. Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and curticosteroids: how much for how long? Ann Rheum Dis 1983; 42: 374-8
31. Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic, clinical and pathologic study. Ann Intern Med 1978; 88: 162-7
32. Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36: 1286-94
33. Salvarani C, Macchioni L, Boiardi L, et al. Soluble interleukin-2 receptors in polymyalgia rheumatica/giant cell arteritis: clinical and laboratory correlations. J Rheumatol 1992; 19: 1100-6
34. Macchioni L, Boiardi L, Salvarani C, et al. Elevated soluble intercellular adhesion molecule-1 in the serum of patients with polymyalgia rheumatica: influence of the steroid treatment. J Rheumatol 1994; 21: 1860-4
35. Salvarani C, Boiardi L, Macchioni L, et al. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1995; 54: 640-4
36. Boiardi L, Salvarani C, Macchioni P, et al. CD8 lymphocyte subsets in active polymyalgia rheumatica: comparison with elderly-onset and adult rheumatoid arthritis and influence of prednisone therapy Br J Rheumatol 1996; 35: 642-8
37. Evans JM, Batts KP, Hunder GG. Persistent giant cell arteritis despite corticosteroid treatment. Mayo Clin Proc 1994; 69: 1060-1
38. Meliconi R, Pulsatelli L, Salvarani C, et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica: quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 1996; 39: 1199-207
39. Rubinow A, Brandt KD, Cohen AS, et al. latrogenic morbidity accompanying suppression of temporal arteritis by adrenal corticosteroids. Ann Ophthalmol 1984; 16: 258-65
40. Delecoeuillerie G, Joly P, Cohen de Lara A, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11-year survey of 210 patients). Ann Rheum Dis 1988; 47: 733-9
41. Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994; 21: 1283-6
42. Sunku J, Gabriel SE, Salvarani C, et al. Long-term outcome of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. In press
43. Hunder GG, Sheps SG, Allen GL, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975; 82: 613-8
44. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-7
45. Ferraccioli GF, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996; 23: 624-8
46. Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996; 55: 218-23
47. Utsinger PD. Treatment of steroid non-responsive giant cell arteritis (GCA) with cytoxan [abstract]. Arthritis Rheum 1982; 25 Suppl.: S31
48. Doury P, Pattin S, Eulry F, et al. The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 1983; 30: 689-90
49. DeSilva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double blind study. Ann Rheum Dis 1986; 45: 136-8
50. Wendling D, Hory B, Blanc D. Cyclosporine: a new adjuvant therapy for giant cell arteritis [letter]? Arthritis Rheum 1985; 28: 1078-9
51. Lauwerys BR, Puttemans T, Houssian FA, et al. Color Doppler sonography of the temporal arteries in giant cell arteritis and polymyalgia rheumatica. J Rheumatol 1997; 24: 1570-4